Cardiovascular Safety and Fracture Prevention Effectiveness of Denosumab Versus Oral Bisphosphonates in Patients Receiving Dialysis
Annals of Internal Medicine · 2025-02 · 178 (2) · 167-176
DOI: 10.7326/annals-24-03237 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Annals of Internal Medicine, 2025-02. Verfasst von Soichiro Masuda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopedic Surgery, Kyoto City Hospital, and Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto U…. Hauptthemen laut MEDLINE: Denosumab, Bone Density Conservation Agents, Renal Dialysis, Diphosphonates. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Dialysis patients have high rates of fracture morbidity, but evidence on optimal management strategies for osteoporosis is scarce. OBJECTIVE: To determine the risk for cardiovascular events and fracture prevention effects with denosumab compared with oral bisphosphonates in dialysis-dependent patients. DESIGN: An observational study that attempts to emulate a target trial. SETTING: A Japanese administrative claims database (April 2014 to October 2022). PATIENTS: Adults aged 50 years or older who have initiated denosumab or oral bisphosphonates for osteoporosis in dialysis-dependent patients. MEASUREMENTS: The safety outcome was major adverse cardiac events (MACE). The effectiveness outcome was a composite of all fractures. Follow-up was 3 years. RESULTS: A total of 1032 patients were identified (658 denosumab users and 374 oral bisphosphonate users). Overall average age was 74.5 years, and 62.9% were women. The weighted 3-year risk difference for MACE was 8.2% (95% CI, -0.2% to 16.7%), with a weighted 3-year risk ratio of 1.36 (CI, 0.99 to 1.87). The weighted 3-year risk difference for composite fractures was -5.3% (CI, -11.3% to -0.6%), and the weighted 3-year risk ratio was 0.55 (CI, 0.28 to 0.93). LIMITATIONS: Lack of clinical data on kidney or osteoporosis disease severity and cardiovascular or other metabolic risk with residual confounding. Safety outcomes did not include kidney end points. CONCLUSION: It was estimated that, compared with oral bisphosphonates, denosumab lowered the risk for fractures by 45% and increased the risk for MACE by 36%. The estimates, however, are imprecise and need to be confirmed in future studies. PRIMARY FUNDING SOURCE: None.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Orthopedic Surgery, Kyoto City Hospital, and Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan (S.Masuda).
- Department of Pharmacoepidemiology and Department of Digital Health and Epidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan (T.F.).
- Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan (S.Matsuda).
- Department of Pharmacoepidemiology, Graduate School of Medicine and Public Health, Kyoto University, Kyoto, Japan (K.K.).
ORCID-Profile: Soichiro Masuda, Toshiki Fukasawa, Shuichi Matsuda
Zitieren
APA
Masuda, S., Fukasawa, T., Matsuda, S., & Kawakami, K. (2025). Cardiovascular Safety and Fracture Prevention Effectiveness of Denosumab Versus Oral Bisphosphonates in Patients Receiving Dialysis. Annals of Internal Medicine, 178(2), 167-176. https://doi.org/10.7326/annals-24-03237
Vancouver
Masuda S, Fukasawa T, Matsuda S, Kawakami K. Cardiovascular Safety and Fracture Prevention Effectiveness of Denosumab Versus Oral Bisphosphonates in Patients Receiving Dialysis. Annals of Internal Medicine. 2025;178(2):167-176. doi:10.7326/annals-24-03237
BibTeX
@article{Masuda2025,
author = {Masuda, Soichiro and Fukasawa, Toshiki and Matsuda, Shuichi and Kawakami, Koji},
title = {Cardiovascular Safety and Fracture Prevention Effectiveness of Denosumab Versus Oral Bisphosphonates in Patients Receiving Dialysis},
journal = {Annals of Internal Medicine},
year = {2025},
volume = {178},
number = {2},
pages = {167--176},
doi = {10.7326/annals-24-03237}
}
EUVIMED